avian, birds, worldwide, influenza , Drug Views, drugs, Medical, Information, Health, Drugs, Conditions, Pharmacy, Pills http://www.drugviews.com/articles.php en-us Ateom.com - Website Power Tools body to help eliminate the contamination. The NanoDTPA™ capsule is a unique orally-bioavailable ]]> Mon, 30 Aug 2010 09:22:00 -0400 http://www.drugviews.com/articles.php?t=Nanotherapeutics-files-NanoDTPA-IND-for-treatment-of-radiation-exposure cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."]]> Thu, 26 Aug 2010 23:28:28 -0400 http://www.drugviews.com/articles.php?t=Aethlon-Medical-receives-approval-for-Chronic-HCV-Infection-treatment cancer, today announced that it has entered into an agreement with GVK Biosciences to expand the opportunity for Aethlon to commercialize its Hemopurifier treatment technology at three to five new clinical centers in India.]]> Wed, 18 Aug 2010 09:04:00 -0400 http://www.drugviews.com/articles.php?t=Aethlon-Medical-signs-agreement-with-GVK-BIO-to-expand-Hemopurifier-technology-in-India product in traveler and military markets]]> Tue, 17 Aug 2010 05:22:00 -0400 http://www.drugviews.com/articles.php?t=Intercell-reports-significant-increase-in-second-quarter-revenue Mon, 16 Aug 2010 07:11:57 -0400 http://www.drugviews.com/articles.php?t=Sinovac-Biotech-second-quarter-2010-sales-increase-131-to-10-3-million joint venture to develop, manufacture, and commercialize a multivalent, cross-protective human vaccine to protect against influenza caused by a broad range of circulating H5 influenza strains.]]> Thu, 12 Aug 2010 02:35:32 -0400 http://www.drugviews.com/articles.php?t=TLV-Emergent-BioSolutions-form-joint-venture-to-develop-broad-spectrum-pandemic-flu-vaccine Medicago USA Inc., a wholly owned subsidiary of Medicago Inc., a clinical-stage biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has been awarded a $21 Million grant from the Defense Advanced Research Projects Agency, Broad Agency Announcement, Defense Sciences Research & Technology to demonstrate the scalable manufacturing of its plant-expressed ]]> Wed, 11 Aug 2010 06:36:49 -0400 http://www.drugviews.com/articles.php?t=Medicago-USA-awarded-21M-to-develop-vaccine-facility-in-Research-Triangle-Park anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."]]> Tue, 20 Jul 2010 05:23:05 -0400 http://www.drugviews.com/articles.php?t=NanoViricides-presents-study-results-of-nanoviricides-anti-Ebola-agents severe Foot and Mouth Disease (FMD) outbreaks after recording an increase of the Replikin Count (ref. 1) of the FMD Virus (FMDV) to its highest level in 52 years. Based on these findings, a new synthetic Replikins Trans-Strain FMD Vaccine, called TransFMDV(TM), has been developed and is now available. The announcement was made at the ]]> Sat, 17 Jul 2010 04:20:00 -0400 http://www.drugviews.com/articles.php?t=BioRadar-develops-TransFMDV-for-Foot-and-Mouth-Disease cancer, announced today that it has filed a provisional patent on behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to the development of an assay that will allow researchers to detect exosomes in blood and other fluids.]]> Thu, 08 Jul 2010 05:08:18 -0400 http://www.drugviews.com/articles.php?t=Aethlon-Medical-files-provisional-patent-on-behalf-of-ESI-for-exosome-detection-assay new, highly conserved molecular target on the influenza A virus and demonstrated that human antibodies against this target are protective in animal models of seasonal and highly-pathogenic avian influenza. The work was conducted by researchers at Theraclone Sciences, with collaborators at University of Wisconsin-Madison, University of Tokyo and Johns Hopkins University; and is reported this week in the online Early ]]> Tue, 29 Jun 2010 05:20:21 -0400 http://www.drugviews.com/articles.php?t=Rare-human-antibodies-protect-mice-from-lethal-strains-of-influenza Fri, 18 Jun 2010 02:14:00 -0400 http://www.drugviews.com/articles.php?t=Mount-Sinai-School-of-Medicine-Alnylam-collaborate-to-develop-microRNA-based-attenuated-influenza-viruses against cancers and infectious diseases, announced today that it has immunized its first subject in a U.S. Phase I clinical trial to evaluate its SynCon™ H5N1 (avian) influenza DNA vaccine, VGX-3400X.]]> Tue, 15 Jun 2010 07:08:29 -0400 http://www.drugviews.com/articles.php?t=Inovio-commences-immunization-in-U-S-Phase-I-clinical-trial-of-SynCon-H5N1-influenza-DNA-vaccine Fri, 11 Jun 2010 07:07:20 -0400 http://www.drugviews.com/articles.php?t=Investment-report-on-Novavax anti-HIV drug candidates demonstrated efficacy in the recently completed cell culture studies using two distinctly different HIV-1 isolates. The studies were performed in the laboratory of Carol Lackman-Smith at the Southern Research Institute, Frederick, Maryland.]]> Tue, 08 Jun 2010 09:59:19 -0400 http://www.drugviews.com/articles.php?t=NanoViricides-anti-HIV-drug-candidates-demonstrate-efficacy-in-cell-culture-studies-with-HIV-1-isolates Biologists at the California Institute of Technology have pinpointed molecular changes that helped allow the global spread of resistance to the antiviral medication Tamiflu (oseltamivir) among strains of the seasonal H1N1 flu virus.]]> Fri, 04 Jun 2010 07:07:00 -0400 http://www.drugviews.com/articles.php?t=Caltech-biologists-pinpoint-molecular-changes-that-help-allow-global-spread-of-resistance-to-Tamiflu drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.]]> Wed, 02 Jun 2010 02:44:11 -0400 http://www.drugviews.com/articles.php?t=Anti-Dengue-drug-candidates-demonstrate-efficacy-in-preliminary-cell-culture-studies kill infectious pathogens, today issued its Interim Management Statement covering the period January 1, 2010, to March 31, 2010.]]> Fri, 28 May 2010 08:25:56 -0400 http://www.drugviews.com/articles.php?t=PuriCore-sales-decreases-9-9-to-10-0-million-for-first-quarter-2010 kill infectious pathogens, today announced its Final Results for the year ending December 31, 2009, and the availability of its 2009 annual report on its website.]]> Fri, 28 May 2010 08:11:23 -0400 http://www.drugviews.com/articles.php?t=PuriCore-revenue-increases-28-to-40-0-million-for-year-ending-December-31-2009 Mon, 24 May 2010 08:29:59 -0400 http://www.drugviews.com/articles.php?t=NanoViricides-reports-2-95M-in-cash-305-000-in-prepaid-expenses-for-quarter-ended-March-31-2010